Timber Hill’s Vertex Pharmaceuticals VRTX Stock Holding History

Timber Hill’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-53,600	Closed	-$5.86M	–	1829
2017 Q1	$5.86M	Buy	53,600 +35,300	+193%	+$3.11M	0.04%	288
2016 Q4	$1.35M	Sell	18,300 -12,700	-41%	-$1.03M	0.01%	1108
2016 Q3	$2.7M	Buy	31,000 +14,700	+90%	+$1.39M	0.01%	691
2016 Q2	$1.4M	Buy	16,300 +7,800	+92%	+$674K	0.01%	1079
2016 Q1	$676K	Sell	8,500 -2,400	-22%	-$217K	﹤0.01%	1443
2015 Q4	$1.37M	Sell	10,900 -14,000	-56%	-$1.69M	0.01%	1168
2015 Q3	$2.59M	Sell	24,900 -1,400	-5%	-$180K	0.01%	874
2015 Q2	$3.25M	Buy	26,300 +1,300	+5%	+$164K	0.01%	804
2015 Q1	$2.95M	Buy	+25,000	New	+$3M	0.01%	820
2014 Q4	–	Sell	-9,700	Closed	-$1.09M	–	2754
2014 Q3	$1.09M	Sell	9,700 -15,500	-62%	-$1.48M	﹤0.01%	1539
2014 Q2	$2.39M	Sell	25,200 -17,800	-41%	-$1.25M	0.01%	1052
2014 Q1	$3.04M	Sell	43,000 -77,800	-64%	-$6.16M	0.01%	891
2013 Q4	$8.97M	Buy	120,800 +30,100	+33%	+$2.1M	0.03%	471
2013 Q3	$6.88M	Sell	90,700 -43,000	-32%	-$3.42M	0.02%	666
2013 Q2	$10.7M	Buy	+133,700	New	+$9.85M	0.04%	414

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Timber Hill's VRTX Position: Q2 2018 in Review

Timber Hill sold out of Vertex Pharmaceuticals (VRTX) in Q2 2018, closing a stake of 6,405 shares — an estimated $1.04M sold.

Timber Hill first reported a position in VRTX in Q3 2013 and held it in 5 quarters. The position peaked at $1.79M in Q2 2014. 690 funds tracked by Wall St. Rank hold VRTX as of Q2 2018.

Timber Hill reported no remaining Vertex Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Timber Hill sold 6,405 Vertex Pharmaceuticals shares in Q2 2018, an estimated $1.04M.
Timber Hill first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 5 quarters.
Timber Hill's Vertex Pharmaceuticals position peaked at $1.79M in Q2 2014.
690 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2018.

Based on Timber Hill's 13F filing for Q2 2018, filed 9 Aug 2018.